NCT06170294View on ClinicalTrials.gov

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

TCR-MAGE-A4 T-Cells

"* Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~* MAGE-A4-directed T cell receptor-engineered T Cells"

Trial Locations (1)

100142

RECRUITING

Department of GI Oncology,Peking University Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY

lead

Peking University

OTHER